ELTX
Elicio Therapeutics, Inc.
Recent 8-K filings for ELTX
Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.
-
May 11, 2026 20:09 UTC earnings item 2.02item 9.01
Q1 net loss $11.8M ($0.65/sh); Phase 2 DFS readout mid-2026; cash runway into Q4
source · ELTX on sec.gov